Here's all you need to know about India's first of its kind Covid vaccine: The iNCOVACC is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results. The vaccine was developed in partnership with Washington University, St.
Louis, which had designed and developed the recombinant adenoviral vectored construct and evaluated in preclinical studies for efficacy. The intranasal vaccine is stable at 2-8°C for easy storage and distribution and has been designed for efficient distribution and easy pain free administration. This vaccine has been specifically formulated to allow intranasal delivery through nasal drops.
The nasal delivery system has been designed and developed to be cost-effective in low and middle-income countries. According to the company, iNCOVACC is the world’s first intranasal vaccine for covid-19 to have received approval for a primary two-dose schedule, and as a heterologous booster dose. As a needle-less vaccine, iNCOVACC will be India’s first such booster dose.
Covid-19.rehab - the latest news concerning the spread of the SARS-CoV-2 coronavirus (formerly 2019-nCoV), as well as the infectious disease that it causes COVID-19, in separate countries and in the world as a whole. Current news on the topic of coronavirus SARS-CoV-2. Quarantine, pandemic 2020, epidemic: what is it, when will it come to end, precautions and how to protect yourself from this disease. The most honest news, no fakes! To keep up with the latest news, stay tuned for updates on the site! Every day we will collect news and statistics on coronavirus from around the world for you to be aware of this topic.
Owner: SNOWLAND s.r.o.
Registration certificate 06691200
16200, Na okraji 381/41, Veleslavín, 162 00 Praha 6